Análisis de coste-efectividad de la vacunación frente al virus del papiloma humano tipos 6, 11, 16 y 18 en España

These analyses demonstrate that adding a four-valent HPV vaccine to the current screening programme in Spain is a cost-effective strategy for reducing the burden of cervical cancer, pre-cancerous lesions and genital warts.